PlainRecalls
FDA Drug Moderate Class II Ongoing

Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01

Reported: December 28, 2022 Initiated: December 16, 2022 #D-0087-2023

Product Description

Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01

Reason for Recall

Failed Impurities/Degradation Specifications

Details

Recalling Firm
Aurolife Pharma, LLC
Units Affected
7344 bottles
Distribution
Nationwide in the USA and Puerto Rico.
Location
Dayton, NJ

Frequently Asked Questions

What product was recalled?
Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01. Recalled by Aurolife Pharma, LLC. Units affected: 7344 bottles.
Why was this product recalled?
Failed Impurities/Degradation Specifications
Which agency issued this recall?
This recall was issued by the FDA Drug on December 28, 2022. Severity: Moderate. Recall number: D-0087-2023.